BCDA BioCardia

BioCardia Regains Compliance with Nasdaq Listing Requirements

BioCardia Regains Compliance with Nasdaq Listing Requirements

SUNNYVALE, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announces it has regained compliance with the Nasdaq Capital Market’s Listing Requirements (the “Listing Requirements”). This confirmation follows the Company’s successful efforts to improve its balance sheet, including raising new capital to continue development of its therapeutic candidates and advance its approved products.

Specifically, on October 1, 2025, BioCardia received written notice (the “Notice”) from Nasdaq confirming that the Nasdaq Staff has determined the Company complies with Listing Rule 5550(b)(1), (the “Equity Rule”). Accordingly, the Company’s securities will continue to be listed on the Nasdaq Capital Market under the symbol “BCDA.”

About BioCardia:

BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms, and soon the Heart3DTM fusion imaging platform. BioCardia selectively partners on biotherapeutic delivery with peers developing important biologic therapies. For more information visit

Forward Looking Statements

This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, references to the Company’s continued ability to raise capital to continue development of its therapeutic candidates and advance its approved products and maintain compliance with Listing Requirements. These forward-looking statements are made as of the date of this press release, and BioCardia assumes no obligation to update the forward-looking statements.

We may use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release as a result of one or more risk factors. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Additional factors that could materially affect actual results can be found in BioCardia’s Form 10-K filed with the Securities and Exchange Commission on March 26, 2025, under the caption titled “Risk Factors” and in its subsequently filed Quarterly Reports on Form 10-Q. BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.



Media Contact:
Miranda Peto, Investor Relations
Email:  
Phone: 650-226-0120

Investor Contact:
David McClung, Chief Financial Officer
Email:  
Phone: 650-226-0120
EN
02/10/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioCardia

 PRESS RELEASE

BioCardia Regains Compliance with Nasdaq Listing Requirements

BioCardia Regains Compliance with Nasdaq Listing Requirements SUNNYVALE, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announces it has regained compliance with the Nasdaq Capital Market’s Listing Requirements (the “Listing Requirements”). This confirmation follows the Company’s successful efforts to improve its balance sheet, including raising new capital to continue development of its therapeutic candidates and advance its approved products. Specifically, on Oc...

 PRESS RELEASE

BioCardia Announces Pricing of Up To $12 Million Public Offering

BioCardia Announces Pricing of Up To $12 Million Public Offering $6 million upfront with up to an additional $6 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants SUNNYVALE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA] (“BioCardia” or the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the pricing of a public offering of an aggregate of 4,800,000 shares of its common stock and short-term warrants to purchase up to 4,800,00...

 PRESS RELEASE

BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Lin...

BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Line Data of Roll-in Cohort Show Improved Exercise Tolerance and Reduced Angina Episodes at Six-Month Primary Follow-up SUNNYVALE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the primary endpoint results of the open label roll-in cohort of the CardiAMP® Cell Therapy in Chronic Myocardial Ischemia Trial. Results from the open label roll-in cohort patients havin...

 PRESS RELEASE

BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Ann...

BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025 SUNNYVALE, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- - [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that BioCardia’s President and CEO, Peter Altman, PhD., will present a corporate update, including recent progress toward milestones, at the H. C. Wainwright 27th Annual Global Investment Conference at the Lotte Palace Hotel in New York City. Dr. Altm...

 PRESS RELEASE

BioCardia and CART-Tech Announce Exclusive Partnership to Develop and ...

BioCardia and CART-Tech Announce Exclusive Partnership to Develop and Commercialize Heart3D™ Fusion Imaging for Interventional Cardiology SUNNYVALE, Calif. and UTRECHT, Netherlands, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, and CART-Tech, B.V., a provider of vendor independent platform technology for augmented fluoroscopy during cardiac interventions, today announce that they have entered into an exclusive development and commercialization agreemen...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch